<h4>Background</h4>Tumor necrosis factor-α (TNF-α) inhibitors, such as infliximab, adalimumab, and certolizumab pegol are effective agents in the treatment of inflammatory bowel disease. This evidence concerns the gene TNF and inflammatory bowel disease.